105 related articles for article (PubMed ID: 17172464)
1. Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition.
Tian G; Wilkins D; Scott CW
Mol Pharmacol; 2007 Mar; 71(3):902-11. PubMed ID: 17172464
[TBL] [Abstract][Full Text] [Related]
2. Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains.
Malherbe P; Bissantz C; Marcuz A; Kratzeisen C; Zenner MT; Wettstein JG; Ratni H; Riemer C; Spooren W
Mol Pharmacol; 2008 Jun; 73(6):1736-50. PubMed ID: 18308898
[TBL] [Abstract][Full Text] [Related]
3. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
Chung FZ; Wu LH; Tian Y; Vartanian MA; Lee H; Bikker J; Humblet C; Pritchard MC; Raphy J; Suman-Chauhan N
Mol Pharmacol; 1995 Oct; 48(4):711-6. PubMed ID: 7476898
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA; Cato KJ; Scott C; Watson JM; Wood MD; Foxton R; de la Flor R; Jones GA; Kew JN; Cluderay JE; Southam E; Murkitt GS; Gartlon J; Pemberton DJ; Jones DN; Davies CH; Hagan J
Neuropsychopharmacology; 2008 Jun; 33(7):1642-52. PubMed ID: 17728699
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists.
Medhurst AD; Hay DW; Parsons AA; Martin LD; Griswold DE
Br J Pharmacol; 1997 Oct; 122(3):469-76. PubMed ID: 9351503
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of [125I][MePhe7]neurokinin B binding to tachykinin NK3 receptors: evidence for interspecies variance.
Suman-Chauhan N; Grimson P; Guard S; Madden Z; Chung FZ; Watling K; Pinnock R; Woodruff G
Eur J Pharmacol; 1994 Sep; 269(1):65-72. PubMed ID: 7530207
[TBL] [Abstract][Full Text] [Related]
7. Characterization of NK3 receptors in rabbit isolated iris sphincter muscle.
Medhurst AD; Parsons AA; Roberts JC; Hay DW
Br J Pharmacol; 1997 Jan; 120(1):93-101. PubMed ID: 9117105
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells.
Oury-Donat F; Carayon P; Thurneyssen O; Pailhon V; Emonds-Alt X; Soubrié P; Le Fur G
J Pharmacol Exp Ther; 1995 Jul; 274(1):148-54. PubMed ID: 7616392
[TBL] [Abstract][Full Text] [Related]
9. Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization.
Malherbe P; Knoflach F; Marcuz A; Bohnert C; Weber M; Knust H; Ratni H; Spooren W; Ballard TM; Bissantz C
Neuropharmacology; 2014 Nov; 86():259-72. PubMed ID: 25107588
[TBL] [Abstract][Full Text] [Related]
10. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Sarau HM; Griswold DE; Potts W; Foley JJ; Schmidt DB; Webb EF; Martin LD; Brawner ME; Elshourbagy NA; Medhurst AD; Giardina GA; Hay DW
J Pharmacol Exp Ther; 1997 Jun; 281(3):1303-11. PubMed ID: 9190866
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412).
de la Flor R; Dawson LA
Neuropharmacology; 2009 Feb; 56(2):342-9. PubMed ID: 18822303
[TBL] [Abstract][Full Text] [Related]
12. SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor.
Emonds-Alt X; Bichon D; Ducoux JP; Heaulme M; Miloux B; Poncelet M; Proietto V; Van Broeck D; Vilain P; Neliat G
Life Sci; 1995; 56(1):PL27-32. PubMed ID: 7830490
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.
Geldenhuys WJ; Kuzenko SR; Simmons MA
J Med Chem; 2010 Nov; 53(22):8080-8. PubMed ID: 21047106
[TBL] [Abstract][Full Text] [Related]
14. Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.
Malherbe P; Kratzeisen C; Marcuz A; Zenner MT; Nettekoven MH; Ratni H; Wettstein JG; Bissantz C
J Med Chem; 2009 Nov; 52(22):7103-12. PubMed ID: 19817444
[TBL] [Abstract][Full Text] [Related]
15. Development of novel NK3 receptor antagonists with reduced environmental impact.
Yamamoto K; Okazaki S; Ohno H; Matsuda F; Ohkura S; Maeda K; Fujii N; Oishi S
Bioorg Med Chem; 2016 Aug; 24(16):3494-500. PubMed ID: 27298001
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of SR 142801: a new non-peptide antagonist of the neurokinin NK-3 receptor.
Nguyen-Le XK; Nguyen QT; Gobeil F; Pheng LH; Emonds-Alt X; Brelière JC; Regoli D
Pharmacology; 1996 May; 52(5):283-91. PubMed ID: 8807672
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
[TBL] [Abstract][Full Text] [Related]
18. Opinion: NK3 receptor antagonists: the next generation of antipsychotics?
Spooren W; Riemer C; Meltzer H
Nat Rev Drug Discov; 2005 Dec; 4(12):967-75. PubMed ID: 16341062
[TBL] [Abstract][Full Text] [Related]
19. Modulation of peristalsis by NK3 receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised.
Sanger GJ; Tuladhar BR; Brown J; Aziz E; Sivakumar D; Furness JB
Auton Autacoid Pharmacol; 2007 Apr; 27(2):105-11. PubMed ID: 17391280
[TBL] [Abstract][Full Text] [Related]
20. 2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor.
Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Foley JJ; Raveglia LF; Schmidt DB; Rigolio R; Vassallo M; Vecchietti V; Hay DW
J Med Chem; 1996 Jun; 39(12):2281-4. PubMed ID: 8691422
[No Abstract] [Full Text] [Related]
[Next] [New Search]
